Impact Factor 3.831

Frontiers journals are at the top of citation and impact metrics

Mini Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Pharmacol. | doi: 10.3389/fphar.2018.01074

Development and Role in Therapy of Canakinumab in Adult-Onset Still's Disease

  • 1Unità di reumatologia, Dipartimento di Medicina, Università degli Studi di Padova, Italy

Adult-onset Still’s disease (AOSD) is a rare inflammatory disease of unknown aetiology typically characterized by episodes of spiking fever, evanescent rash, arthralgia, leukocytosis and hyperferritinemia. The pivotal role of interleukin (IL)-1 and other pro-inflammatory cytokines gives rise to the development of new targeted therapies. Currently, AOSD patients can benefit from efficient and well tolerated biologic agents, such as IL-1, IL-6 and tumour necrosis factor (TNF)-α antagonists.
Canakinumab, a human monoclonal anti-IL-1β antibody, is indicated for the treatment of different autoinflammatory syndromes in adults, adolescents and children and it has recently been approved for AOSD treatment.
In this article, we summarize the structural and biochemical data describing the molecular interactions between Canakinumab and its target antigen. Some special considerations of the pharmacological properties of Canakinumab are included. We also review the safety, efficacy and tolerability of this drug for the treatment of AOSD.

Keywords: Canakinumab, Adult-onset Still's Disease (AODS), Interleukin-1 Beta (IL-1β), Drug Development, Therapy -

Received: 12 Jun 2018; Accepted: 05 Sep 2018.

Edited by:

Stefania Tacconelli, Università degli Studi G. d'Annunzio Chieti e Pescara, Italy

Reviewed by:

Anna Shcherbina, Pediatric Hematology, Oncology and Immunology them. Dmitry Rogachev, Russia
ANNALISA CHIAVAROLI, Università degli Studi G. d'Annunzio Chieti e Pescara, Italy  

Copyright: © 2018 Galozzi, Baggio, Bindoli, Oliviero and Sfriso. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Paolo Sfriso, Unità di reumatologia, Dipartimento di Medicina, Università degli Studi di Padova, Padova, Italy, paolo.sfriso@unipd.it